The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: Results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI)St George Hosp, Dept Surg, Gray St Kogarah, Sydney, NSW 2217, Australia.
Kishiwada Tokushukai Hosp, Peritoneal Surface Malignancy Ctr, 4-27-1 Kamori Cho, Kishiwada, Osaka 5968522, Japan.
Sao Rafael Hosp, Surg Oncol Unit, Ave Sao Rafael 2152, BR-41253190 Salvador, BA, Brazil.
Manipal Hosp, Manipal Comprehens Canc Ctr, Dept Surg Oncol & Robot Surg, 98 HAL Airport Rd, Bengaluru 560017, Karnataka, India.
Ghent Univ Hosp Belgium, Dept Gastrointestinal Surg, Ghent, Belgium.
Univ Montreal, Hosp Maisonneuve Rosemont, Dept Surg, Montreal, PQ, Canada.
Capital Med Univ, Beijing Shijitan Hosp, Dept Peritoneal Canc Surg, Beijing, Peoples R China.
Aarhus Univ Hosp, Dept Surg, Norrebrogade 44, DK-8000 Aarhus, Denmark.
Hosp Civils Lyon, Dept Surg Oncol, Lyon, France;Lyon Sud Hosp, Lyon Fac Med, Lyon, France.
Hosp Barmherzige Bruder, Dept Gen & Visceral Surg, Regensburg, Germany.
European Interbalkan Med Ctr, Thessaloniki, Greece.
Natl Canc Ctr Singapore, Singapore, Singapore.
Univ Texas MD Anderson Canc Ctr, Surg Oncol, Madrid, Spain.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Upper Abdominal Surgery.
Univ Hosp Zurich, Dept Visceral & Transplantat Surg, Zurich, Switzerland.
Fdn IRCCS Ist Nazl Tumori, Peritoneal Surface Malignancies Unit, Milan, Italy.
Hampshire Hosp Fdn Trust, Peritoneal Malignancy Inst Basingstoke, Adelmaston Rd, Basingstoke RG24 9NA, Hants, England.
Catharina Hosp, Dept Surg, POB 1350, NL-5602 ZA Eindhoven, Netherlands.
Show others and affiliations
2018 (English)In: European Journal of Surgical Oncology, ISSN 0748-7983, E-ISSN 1532-2157, Vol. 44, no 12, p. 1942-1948Article in journal (Refereed) Published
Abstract [en]
Background: At present, selected patients with resectable colorectal peritoneal metastases (CRC-PM) are increasingly treated with a combination therapy of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The aim of this study was to investigate the current worldwide practice.
Methods: HIPEC experts from 19 countries were invited through the Peritoneal Surface Oncology Group International (PSOGI) to complete an online survey concerning their personal expertise and current hospital and country wide practice.
Results: It is estimated that currently more than 3800 patients with CRC-PM (synchronous and metachronous) are annually treated with CRS and HIPEC in 430 centers. Integration of CRS and HIPEC in national guidelines varies, resulting in large treatment disparities between countries. Amongst the experts, there was general agreement on issues related to indication, surgical technique and follow up but less on systemic chemotherapy or proactive strategies.
Conclusion: This international survey demonstrates that CRS and HIPEC is now performed on a large scale for CRC-PM patients. Variation in treatment may result in heterogeneity in surgical and oncological outcomes, emphasising the necessity to reach consensus on several issues of this comprehensive procedure. Future initiatives directed at achieving an international consensus statement are needed.
Place, publisher, year, edition, pages
ELSEVIER SCI LTD , 2018. Vol. 44, no 12, p. 1942-1948
Keywords [en]
Colorectal peritoneal metastases, Cytoreductive surgery, Hyperthermic intraperitoneal chemotherapy
National Category
Surgery
Identifiers
URN: urn:nbn:se:uu:diva-373016DOI: 10.1016/j.ejso.2018.07.003ISI: 000452943200016PubMedID: 30075978OAI: oai:DiVA.org:uu-373016DiVA, id: diva2:1277504
2019-01-102019-01-102019-01-10Bibliographically approved